{"entity":{"id":"array-biopharma","kind":"company","name":"Array BioPharma","aka":["Array BioPharma Inc.","NASDAQ:ARRY"],"tldr":"Array BioPharma, of Boulder, Colorado, developed encorafenib and binimetinib, two pills taken together for melanoma with a BRAF mutation. Pfizer bought the company in 2019.","summary":"Array BioPharma Inc. (formerly Nasdaq: ARRY) was a commercial-stage company in Boulder, Colorado, that discovered and developed targeted small-molecule medicines. At the time of its sale its main products were BRAFTOVI (encorafenib) and MEKTOVI (binimetinib), approved together for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation and being tested in more than 30 trials, including the phase 3 BEACON trial in BRAF-mutant metastatic colorectal cancer. Pfizer agreed on 17 June 2019 to buy Array for USD 48 per share in cash, a total enterprise value of about USD 11.4 billion, through a tender offer, and the merger was completed on 30 July 2019.","asOf":"2026-11-03","links":[{"label":"Pfizer to acquire Array BioPharma (8-K exhibit 99.1, 17 June 2019)","url":"https://www.sec.gov/Archives/edgar/data/1100412/000110465919035823/a19-11481_1ex99d1.htm"},{"label":"Form 8-K: completion of the merger (30 July 2019)","url":"https://www.sec.gov/Archives/edgar/data/1100412/000119312519206255/d733992d8k.htm"}],"tags":[],"related":[],"cancers":["melanoma","colorectal"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["braf","mek"],"drugs":["encorafenib","binimetinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No website is recorded: Array no longer operates under its own name and the redirect of its old domain was not checked. Completion on 30 July 2019 is from Array's 8-K of that date. Founding year not read in a primary source and omitted."],"hq":"Boulder, CO","country":"US","companyType":"biotech","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2019,"amountUsd":11400000000,"source":"https://www.sec.gov/Archives/edgar/data/1100412/000110465919035823/a19-11481_1ex99d1.htm","note":"Pfizer's announcement of 17 June 2019, filed as exhibit 99.1 to Array's 8-K: USD 48 per share in cash, total enterprise value of approximately USD 11.4 billion"}],"acquiredBy":"pfizer"},"route":"/companies/array-biopharma/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/"},{"id":"mek","kind":"target","name":"MEK1/2","route":"/targets/mek/"}],"drug":[{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}